Orgenesis (ORGS) Competitors $2.00 -0.16 (-7.52%) As of 06/12/2025 03:05 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGS vs. XLO, OKUR, KPTI, MDCX, ESLA, ELYM, PLUR, ACRV, SCYX, and LTRNShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Xilio Therapeutics (XLO), OnKure Therapeutics (OKUR), Karyopharm Therapeutics (KPTI), Medicus Pharma (MDCX), Estrella Immunopharma (ESLA), Eliem Therapeutics (ELYM), Pluri (PLUR), Acrivon Therapeutics (ACRV), SCYNEXIS (SCYX), and Lantern Pharma (LTRN). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Its Competitors Xilio Therapeutics OnKure Therapeutics Karyopharm Therapeutics Medicus Pharma Estrella Immunopharma Eliem Therapeutics Pluri Acrivon Therapeutics SCYNEXIS Lantern Pharma Xilio Therapeutics (NASDAQ:XLO) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations, community ranking and profitability. Do institutionals and insiders believe in XLO or ORGS? 54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by insiders. Comparatively, 5.7% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor XLO or ORGS? In the previous week, Xilio Therapeutics had 4 more articles in the media than Orgenesis. MarketBeat recorded 4 mentions for Xilio Therapeutics and 0 mentions for Orgenesis. Xilio Therapeutics' average media sentiment score of 1.02 beat Orgenesis' score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Xilio Therapeutics Positive Orgenesis Neutral Do analysts rate XLO or ORGS? Xilio Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 486.51%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Xilio Therapeutics is more favorable than Orgenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer XLO or ORGS? Xilio Therapeutics received 12 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 76.47% of users gave Xilio Therapeutics an outperform vote. CompanyUnderperformOutperformXilio TherapeuticsOutperform Votes1376.47% Underperform Votes423.53% OrgenesisOutperform Votes1100.00% Underperform VotesNo Votes Which has stronger valuation & earnings, XLO or ORGS? Orgenesis has lower revenue, but higher earnings than Xilio Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXilio Therapeutics$9.27M3.81-$76.40M-$0.84-0.81Orgenesis$662K14.48-$55.36MN/AN/A Which has more risk & volatility, XLO or ORGS? Xilio Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Is XLO or ORGS more profitable? Xilio Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xilio TherapeuticsN/A -211.50% -80.31% Orgenesis -3,827.81%N/A -130.18% SummaryXilio Therapeutics beats Orgenesis on 10 of the 16 factors compared between the two stocks. Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.59M$6.92B$5.61B$8.62BDividend YieldN/A2.54%5.28%4.17%P/E RatioN/A8.6727.1419.96Price / Sales14.48262.53414.30157.63Price / CashN/A65.8538.2534.64Price / Book-0.306.597.074.69Net Income-$55.36M$143.75M$3.23B$248.14M7 Day Performance7.97%0.67%0.71%0.91%1 Month Performance4.31%11.92%9.65%5.71%1 Year PerformanceN/A4.33%32.07%14.71% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesis1.5676 of 5 stars$2.00-7.5%N/AN/A$9.59M$662K0.00150Gap UpXLOXilio Therapeutics3.5736 of 5 stars$0.70-34.6%$4.00+471.3%-35.5%$36.25M$9.27M-0.4170Positive NewsShort Interest ↓Gap DownHigh Trading VolumeOKUROnKure Therapeutics3.3782 of 5 stars$2.65+4.7%$32.33+1,120.1%N/A$35.80MN/A-0.22N/ANews CoverageKPTIKaryopharm Therapeutics4.043 of 5 stars$4.12-1.9%$43.20+948.5%-71.8%$35.60M$142.13M-4.04380MDCXMedicus Pharma1.9966 of 5 stars$2.63+3.1%$23.50+793.5%N/A$35.49MN/A0.00N/AHigh Trading VolumeESLAEstrella Immunopharma2.1537 of 5 stars$0.98-2.9%$16.00+1,532.7%+9.1%$35.44MN/A-3.77N/AShort Interest ↑Gap DownELYMEliem TherapeuticsN/A$1.18-3.3%N/A-85.2%$35.11MN/A-2.239PLURPluri2.2971 of 5 stars$4.47+0.2%$12.00+168.5%-24.8%$35.01M$1.03M-0.80150Short Interest ↑Gap DownACRVAcrivon Therapeutics4.2657 of 5 stars$1.11+5.7%$17.71+1,495.9%-83.2%$34.80MN/A-0.4158News CoveragePositive NewsAnalyst RevisionHigh Trading VolumeSCYXSCYNEXIS0.8825 of 5 stars$0.89+1.7%N/A-62.0%$34.71M$2.63M-1.2060Positive NewsLTRNLantern Pharma2.5921 of 5 stars$3.19+4.6%$25.00+683.7%-42.8%$34.40MN/A-1.7920 Related Companies and Tools Related Companies Xilio Therapeutics Alternatives OnKure Therapeutics Alternatives Karyopharm Therapeutics Alternatives Medicus Pharma Alternatives Estrella Immunopharma Alternatives Eliem Therapeutics Alternatives Pluri Alternatives Acrivon Therapeutics Alternatives SCYNEXIS Alternatives Lantern Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGS) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
